

## Summary of minutes of EUCAST Steering Committee Meeting Madrid, Spain, 16-17 February 2009

### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Dr Christian Giske	CG	SRGA	Sweden
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Arnfinn Sundsfjord	MS	NWGA	Norway
Prof Paul Tulkens	PT	EUCAST	Belgium

### Apologies

Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Antti Hakanen	AH	EUCAST	Finland

<b>1</b>	<b>Chairman's welcome</b>
<b>2</b>	<b>Minutes of meeting of 24-25 November 2008</b> With minor typographical corrections the minutes were accepted as a correct record.
<b>3</b>	<b>Matters arising from minutes of 24-25 November 2008</b> Colistin MIC distributions for <i>Pseudomonas</i> spp. are being collected.  Telithromycin data relating to breakpoints may be provided by Aventis.  EUCAST MIC breakpoint tables are to be provided in pdf format.  The detection of carbapenemase-producing organisms with carbapenem breakpoints and epidemiological cut-offs was discussed.  MIC distributions for "other streptococci" will be examined in order to assist in selecting breakpoints.
<b>4</b>	<b>New drugs</b> The current status of a new quinolone, a new glycopeptides and a new diaminopyrimidine were discussed.
<b>5</b>	<b>Status of EUCAST documents</b> Current status of rationale documents and EUCAST Technical Notes for CMI was reviewed.
<b>6</b>	<b>Expert rules subcommittee</b> The rules tables and the collated comments on version 1 were reviewed. It was suggested that <i>H. Influenzae</i> should be intermediate to macrolides; the reporting of ESBL-producers when they appear susceptible to $\beta$ -lactams is contentious; and some aminoglycoside rules may need amendment.
<b>7</b>	<b>Antifungal susceptibility testing subcommittee</b> Will collaborate informally with workers in USA.
<b>8</b>	<b>Anaerobe subcommittee</b> A review of susceptibility testing of anaerobes is being produced.
<b>9</b>	<b>Mycobacteria subcommittee</b> Options for developments in relation to mycobacteria are being assessed by ECDC.
<b>10</b>	<b>EUCAST publications</b> A document on the value of ECOFFs is being prepared. A paper on screening for carbapenemases is being written. The supplement on expert rules will be delayed until version 2 of the rules is prepared.
<b>11</b>	<b>Organisms/agents requiring breakpoints</b> The list was reviewed and amended.

<b>12</b>	<p><b>Implementation of EUCAST breakpoints</b> Breakpoints will be promoted at the ECCMID workshop, symposium and general meeting.</p> <p>There are difficulties in countries where there is no antibiotic committee and no microbiologists prominent in the area. Promoting national antibiotic committees was an ECDC objective.</p> <p>The website will be an important resource for information on EUCAST breakpoints.</p> <p>The NEQAS EQA programme is no longer publishing individual country breakpoints and expected results will be based on EUCAST breakpoints.</p>
<b>13</b>	<p><b>ECCMID</b> The 4 h educational workshop on susceptibility testing problems will be on the Saturday morning, 16 May; the 2 h symposium on implementation of EUCAST breakpoints and EUCAST methodologies will be on the Tuesday morning, 19 May.</p>
<b>14</b>	<p><b>EUCAST disk diffusion method</b> Approaches to development of the method were discussed.</p>
<b>15</b>	<p><b>ECDC</b> A call for tenders for a disk diffusion method is expected soon. GK attended an ad-hoc ECDC meeting on antimicrobial resistance and healthcare associated infections.</p>
<b>16</b>	<p><b>EMA</b> No new information.</p>
<b>17</b>	<p><b>Oral cephalosporins</b> The draft breakpoint table was reviewed and updated and will be sent for consultation with national breakpoint committees.</p>
<b>18</b>	<p><b><i>M. catarrhalis</i> and iv cephalosporins</b> Agreed to modify breakpoints, and to include a separate column for <i>M. catarrhalis</i> breakpoints.</p>
<b>19</b>	<p><b>Review of glycopeptide breakpoints</b> Following further discussion it was agreed that revised breakpoints will be sent for final email consultation with national breakpoint committees.</p>
<b>20</b>	<p><b>Any other business</b> None.</p>
<b>21</b>	<p><b>Next meetings</b> 19-20 May 2009. Helsinki, Finland (following ECCMID). 27-29 September 2009, Leipzig, Germany. 23-24 November 2009, Nice, France. February 2010, Brussels, Belgium. 13-14 April 2010, Vienna, Austria (following ECCMID).</p>

Ratified summary of minutes of meeting 16-17 February 2008. Prepared by DB, GK and RC